Objective: To evaluate the prospect for clinical use of four novel retinoid compounds (retinoid 1, retinoid 2, retinoid 3 and retinoid 4), which were different structurally from all-trans retinoic acid.
Methods: The effects of the four retinoids on the differentiation and clonal proliferation of NB4 cells and fresh acute promyelocytic leukemia (APL) cells and on the proliferation of normal hematopoietic cells were studied. Cell morphological examination,nitro tetrazolium blue reduction test, cell cycle dynamics, and colony formation assay were used in the study.
Results: Novel retinoids induced differentiation of NB4 and fresh APL cells, and markedly inhibited CFU-L growth of NB4 and fresh APL cells. The activity related to their chemical structures and retinoid 2 was more active. The novel retinoids enhanced the growth of CFU-GM, CFU-E and CFU--Meg of normal bone marrow cells.
Conclusion: These novel retinoids, especially retinoid 2, may regulate the proliferation and differentiation of normal hematopoiesis, induce APL cell differentiation and maturation, and are worthy of further study for clinical use.